The rationale behind the GUIDE-HF trial was mainly to evaluate CardioMEMS effectiveness in a broader population, including patients in NYHA class II and IV, as well as patients without a HF-related hospitalization with increased NT-proBNP levels. The gene discussed is NPPB; the disease is hydrops fetalis.